Onconova Therapeutics, Inc. (ONTX): Price and Financial Metrics
ONTX Price/Volume Stats
| Current price | $0.71 | 52-week high | $1.49 |
| Prev. close | $0.72 | 52-week low | $0.62 |
| Day low | $0.70 | Volume | 37,433 |
| Day high | $0.76 | Avg. volume | 273,246 |
| 50-day MA | $0.84 | Dividend yield | N/A |
| 200-day MA | $0.93 | Market Cap | 14.94M |
ONTX Stock Price Chart Interactive Chart >
ONTX Stock Summary
- With a market capitalization of $16,362,548, ONCONOVA THERAPEUTICS INC has a greater market value than merely 8.35% of US stocks.
- The ratio of debt to operating expenses for ONCONOVA THERAPEUTICS INC is higher than it is for about just 0.33% of US stocks.
- With a price/sales ratio of 72.4, ONCONOVA THERAPEUTICS INC has a higher such ratio than 97.4% of stocks in our set.
- Stocks that are quantitatively similar to ONTX, based on their financial statements, market capitalization, and price volatility, are OGEN, SABS, ABEO, ADAP, and PTN.
- Visit ONTX's SEC page to see the company's official filings. To visit the company's web site, go to www.onconova.com.
ONTX Valuation Summary
- In comparison to the median Healthcare stock, ONTX's price/sales ratio is 3721.05% higher, now standing at 72.6.
- ONTX's price/sales ratio has moved up 64 over the prior 124 months.
Below are key valuation metrics over time for ONTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ONTX | 2023-09-22 | 72.6 | 0.9 | -0.8 | 0.6 |
| ONTX | 2023-09-21 | 73.0 | 0.9 | -0.8 | 0.6 |
| ONTX | 2023-09-20 | 70.8 | 0.8 | -0.8 | 0.7 |
| ONTX | 2023-09-19 | 73.0 | 0.9 | -0.8 | 0.6 |
| ONTX | 2023-09-18 | 74.8 | 0.9 | -0.8 | 0.6 |
| ONTX | 2023-09-15 | 75.2 | 0.9 | -0.8 | 0.6 |
ONTX Growth Metrics
- Its 3 year revenue growth rate is now at -69.13%.
- Its 2 year revenue growth rate is now at -89.57%.
- Its 2 year cash and equivalents growth rate is now at 63.57%.
The table below shows ONTX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.226 | -16.675 | -17.308 |
| 2022-06-30 | 0.226 | -17.042 | -15.363 |
| 2022-03-31 | 0.226 | -17.135 | -15.57 |
| 2021-12-31 | 0.226 | -19.487 | -16.163 |
| 2021-09-30 | 0.227 | -20.69 | -18.828 |
| 2021-06-30 | 0.236 | -22.186 | -21.616 |
ONTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ONTX has a Quality Grade of D, ranking ahead of 8.68% of graded US stocks.
- ONTX's asset turnover comes in at 0.007 -- ranking 403rd of 682 Pharmaceutical Products stocks.
- IDRA, MYMD, and CAPR are the stocks whose asset turnover ratios are most correlated with ONTX.
The table below shows ONTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.007 | 1 | 2.820 |
| 2021-03-31 | 0.008 | 1 | 3.136 |
| 2020-12-31 | 0.009 | 1 | 3.246 |
| 2020-09-30 | 0.007 | 1 | 3.342 |
| 2020-06-30 | 0.009 | 1 | 3.259 |
| 2020-03-31 | 0.123 | 1 | 2.890 |
ONTX Price Target
For more insight on analysts targets of ONTX, see our ONTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $0.30 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Onconova Therapeutics, Inc. (ONTX) Company Bio
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer.
Latest ONTX News From Around the Web
Below are the latest news stories about ONCONOVA THERAPEUTICS INC that investors may wish to consider to help them evaluate ONTX as an investment opportunity.
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV CongressNEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract reporting the use of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB) associated with advanced/metastatic squamous cell carcinoma (SCC) will be presented in the Late Breaking News s |
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment ConferenceNEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Presentation Details Date/Time:Monday, September 11, 2023, available on-line be |
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call TranscriptOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call Transcript August 10, 2023 Onconova Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.29. Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty] Dr. Steve Fruchtman: Sarah, excuse me, you are coming in and out […] |
Q2 2023 Onconova Therapeutics Inc Earnings CallQ2 2023 Onconova Therapeutics Inc Earnings Call |
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial ResultsAnticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans are underway for a registrational trial with rigosertib in patients with RDEB-associated squamous cell carcinoma based on a constructive Type B FDA meeting held in June Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 NEWTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), |
ONTX Price Returns
| 1-mo | N/A |
| 3-mo | -33.64% |
| 6-mo | N/A |
| 1-year | -18.87% |
| 3-year | -82.60% |
| 5-year | -99.22% |
| YTD | 9.96% |
| 2022 | -74.68% |
| 2021 | -63.50% |
| 2020 | 21.62% |
| 2019 | -81.85% |
| 2018 | -90.62% |
Continue Researching ONTX
Want to see what other sources are saying about Onconova Therapeutics Inc's financials and stock price? Try the links below:Onconova Therapeutics Inc (ONTX) Stock Price | Nasdaq
Onconova Therapeutics Inc (ONTX) Stock Quote, History and News - Yahoo Finance
Onconova Therapeutics Inc (ONTX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...